Business Context and Reporting Period
This Form 8-K is filed by Atossa Therapeutics, Inc. (Nasdaq: ATOS) on February 17, 2026. The report addresses the Company's status regarding its listing on The Nasdaq Capital Market.
Key Financial Metrics
This filing is a current report regarding corporate governance and listing status. It does not provide financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics.
Material Changes
The primary material event is the resolution of a prior listing deficiency:
- Regained Compliance: The Company received notification from Nasdaq that it has regained compliance with Listing Rule 5550(a)(2) regarding the minimum closing bid price.
- Requirement Met: The Company successfully maintained a minimum closing bid price of $1.00 per share for 10 consecutive trading days, concluding on February 13, 2026.
- Outcome: The Company's common stock will continue to be listed and traded on The Nasdaq Capital Market.
Outlook, Risks, and Management Commentary
Management Commentary: The filing confirms that the Company utilized an extension granted on August 21, 2025, which extended the compliance deadline by 180 days to February 17, 2026. The Company met the requirements within this extended period.
Risks and Contingencies: The immediate risk of delisting due to failure to maintain the minimum bid price has been resolved as of the report date. No other risks or unusual items are disclosed in this specific filing.
Investor Verification Checklist
- Verify the current trading price of ATOS to ensure it remains above the $1.00 threshold to avoid future non-compliance notices.
- Review the Company's previous 8-K filings from February 2025 and August 2025 to understand the full timeline of the compliance extension.
- Confirm the continued listing status on The Nasdaq Capital Market via the exchange's official website.